Preladenant

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NamePreladenant
Drug Alias NamePreladenantum普瑞迪南普瑞丁奈瑞德南特SCH-420814 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A2a receptor antagonists
TargetsAdenosine A2a receptor
Therapy Area/IndicationsNeurodegenerative DiseasesDyskinesia, Drug-InducedAkathisia, Drug-Induced +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsN/A
Inactive IndicationsNeurodegenerative DiseasesDyskinesia, Drug-InducedAkathisia, Drug-Induced +[10] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG